Ownership Summary
Recent 13F filings as of December 2025 show that 8 institutional investors hold a position in Artelo Biosciences, Inc. (NASDAQ:ARTL).
- Institutional ownership in Artelo Biosciences edged up to 13.7% in December 2025, compared to 5.5% in September 2025.
- Institutional share ownership changed by 472.98% QoQ, while the number of institutional owners saw an increase of 33.33% YoY.
- Of these 8 institutional investors, 7 increased their holdings in Artelo Biosciences, while 0 of them reduced positions, and 1 investors maintained their exposure.
- Collectively, institutional investors increased their stake in Artelo Biosciences to 81.64K shares as of December 2025, a change that is up by 67.39K shares quarter on quarter and up 47.13K shares year over year.
- UBS Group AG continues to be the largest institutional holder of Artelo Biosciences as of December 31, 2025, with a position of 33.62K shares, representing 5.63% of the company's outstanding stock.
- Among the most significant buyers of Artelo Biosciences during December 2025 were UBS Group AG (33.41K), TWO SIGMA INVESTMENTS, LP (20.67K), GEODE CAPITAL MANAGEMENT, LLC (11.40K), Tower Research Capital LLC (TRC) (1.90K), BANK OF AMERICA CORP /DE/ (6).
- The top 8 institutional holders of Artelo Biosciences for the quarter ending December 2025 included UBS Group AG (33.62K), TWO SIGMA INVESTMENTS, LP (20.67K), VANGUARD GROUP INC (14.03K), GEODE CAPITAL MANAGEMENT, LLC (11.40K), Tower Research Capital LLC (TRC) (1.90K), BANK OF AMERICA CORP /DE/ (17), OSAIC HOLDINGS, INC. (1), CWM, LLC (1).